# Pax6 regulates the morphological and electrophysiological development of mouse prethalamic neurons

## Tian Tian<sup>1,2,\*</sup>, Idoia Quintana-Urzainqui<sup>1</sup>, Zrinko Kozić<sup>1</sup>, Thomas Pratt<sup>1</sup>, David J. Price<sup>1</sup>


<sup>1</sup>Simons Initiative for the Developing Brain, Hugh Robson Building, George Square, Edinburgh EH8 9XD, UK

<sup>2</sup>Lead Contact: ttian@ed.ac.uk \* Correspondence: ttian@ed.ac.uk

### Summary

Pax6 is a well-known regulator of early neuroepithelial progenitor development. We discovered that it can also influence the later morphological and functional development of neurons in the prethalamus, which are unusual in retaining Pax6 expression as they mature. We used conditional mutagenesis to induce Pax6 loss-of-function mutations in prethalamic neurons and found that they showed developmental abnormalities when grown in vitro. Their rates of neurite elongation were disturbed and their axon initial segments were longer and extended further away from the soma than their control counterparts. They exhibited altered electrophysiological properties, including abnormal action potential (AP) waveforms and enhanced excitability, with abnormally low levels of current stimulus able to initiate APs. Our results significantly broaden the known functions of Pax6, suggesting that it has direct cell autonomous effects on the structural and functional development of some neurons. They provide new insights into the genetic regulation of the later stages of neurodevelopment.

## Graphical abstract



## Keywords

Pax6, transcription factors, prethalamus, post-mitotic neurons, neuronal morphogenesis, axon initial segment, neuronal activity

## Introduction

From a very early stage of its development, the neuroepithelium is patterned by the regional expression of transcription factors that specify the subsequent development of each region. The extent to which these transcription factors influence the later development of the functional properties of neurons is much less clear. We studied the transcription factor Pax6, a well-known regulator of early neural development (Hanson and Van Heyningen, 1995; Mi *et al.*, 2013; Manuel *et al.*, 2015; Cvekl and Callaerts, 2017). Pax6 expression in the mouse neuroepithelium is first detected soon after neural tube closure, around embryonic day 8.0 (E8.0), and continues in specific forebrain progenitors, where it has pivotal functions in diverse early developmental processes (Hanson and Van Heyningen, 1995; Engelkamp *et al.*, 1999; Manuel *et al.*, 2015; Cvekl and Callaerts, 2017). In most of these regions, Pax6's expression is lost in cells exiting the cell cycle and embarking on their journey of migration and differentiation (Duan *et al.*, 2013; Kikkawa *et al.*, 2019). Unusually, however, strong Pax6 expression is retained by many post-mitotic neurons in the mantle zone of the prethalamus (Caballero *et al.*, 2014).

We previously reported the generation of an RNAseq dataset showing changes in gene expression in the prethalamus following acute Pax6 deletion at the onset of neurogenesis (Quintana-Urzainqui *et al.*, 2018). We re-examined this dataset and found an upregulated expression of genes involved in neuronal maturation, including morphogenesis and ion transport. We then used a disassociated cell culture method to test how Pax6 deletion affected the development of prethalamic neurons. This approach was selected to increase the likelihood of detecting cell autonomous effects by limiting the possible indirect consequences of other cellular and anatomical abnormalities known to occur in the brain following Pax6 removal (Stoykova *et al.*, 1996; Georgala, Carr and Price, 2011; Mi *et al.*, 2013; Caballero *et al.*, 2014; Quintana-Urzainqui *et al.*, 2018, 2020). We found that the neurites of Pax6-deleted prethalamic neurons grew at abnormal speed, that their axon initial segments (AISs) tended to be longer and to extend further from the soma and that their electrophysiological properties were altered. Our results revealed that Pax6 is not only an early regulator of neuroepithelial development and regionalization but is

also required later for the structural and functional development of prethalamic neurons.

## Results

## Prethalamic Pax6 deletion caused upregulation of genes involved in neuronal morphogenesis and ion transport


At E13.5, Pax6 is expressed in the cortical, thalamic and prethalamic ventricular zone and in a population of post-mitotic cells in the prethalamus (Figure 1A-A'). We interrogated an existing RNAseq data set that showed significant transcriptional changes in over 3500 genes (adjusted p < 0.05) in the E13.5 prethalamus after acute deletion of Pax6 (Quintana-Urzainqui *et al.*, 2018). Gene ontology (GO) term enrichment analysis on these genes revealed 495 upregulated and 125 downregulated GO terms (Supplementary Table 1). While the downregulated GO terms were mostly related to cell cycle, translation or cellular metabolic processes, many of the upregulated GO terms were related to post-mitotic events (Supplementary Table 1). Among the top 200 upregulated GO terms, 25 related to neuronal morphogenesis and 12 to ion transport. After removing child terms, 14 GO terms were related to neuronal morphogenesis and 7 were related to ion transport (Figure 1C-D, Supplementary Table1).

Further inspection of the dataset showed that Pax6 loss upregulated genes important for the actin and microtubule cytoskeleton during neuritogenesis, for axon specification and for neurite elongation (Supplementary Table 2). In other systems, upregulation of these effector genes increased actin nucleation, actin bundling, microtubule assembly and bidirectional intracellular transportation, which have been shown to augment axon/neurite elongation (Reinhard, Jarchau and Walter, 2001; Da Silva and Dotti, 2002; Fukata *et al.*, 2002; Witte and Bradke, 2008; Norris, Dyer and Lundquist, 2009; Stiess and Bradke, 2011; Flynn, 2013; Sainath and Gallo, 2015). Pax6 loss also upregulated genes involved in relaying extracellular signals to both the actin and microtubule cytoskeleton. These included several guanine exchange factors (GEFs) that relay membrane-signalling activities to members of the Rho GTPases, and several Rho GTPases themselves (Kunisaki *et al.*, 2006; Ueda *et al.*,


2008; Li *et al.*, 2009; Namekata *et al.*, 2010; Xiao *et al.*, 2013). Pax6 loss also upregulated genes that can regulate membrane curvature in order to accommodate cytoskeletal changes during neurite outgrowth and genes encoding several components of the PAR3/6 complex (Barnes and Polleux, 2009; Coutinho-Budd *et al.*, 2012; Quan and Robinson, 2013). The PAR3/6 complex plays a vital role during the establishment of neuronal polarity by mediating rearrangements of the cytoskeleton and plasma membrane structures in response to localised activation of membrane receptors (Nishimura *et al.*, 2004; Shi *et al.*, 2004; Barnes and Polleux, 2009; Lalli, 2014).

The AIS is located at the most proximal end of the axon where it functions as a physiological and physical bridge between the somatodendritic and axonal domains and as the site where action potentials usually initiate (Kole and Stuart, 2008; Kole *et al.*, 2008; Rasband, 2010; Leterrier, 2018). Genes encoding the cytoskeletal components of the AIS were also upregulated (Supplementary Table 2), including the cytoskeletal scaffold protein AnkyrinG (AnkG, also known as Ank3) and  $\beta$ IV Spectrin (Sptbn4). In neurons, AnkG is restricted to the AIS and nodes of Ranvier and is considered a master organizer of AIS assembly as it tethers high densities of specific types of voltage gated ion channels and anchors itself to the underlying actin cytoskeleton via  $\beta$ IV Spectrin (Rasband, 2010; Leterrier, 2018). Genes encoding voltage gated sodium channels (VGSCs) that show concentrated distributions within the AIS were also upregulated, as were genes that encode various voltage-gated ion channels expressed within the somatodendritic domain (Lai and Jan, 2006; Hu *et al.*, 2009).


Based on the above analysis, we hypothesised that Pax6 affects the development of neuronal morphology, the formation of the AIS and the activity of prethalamic neurons. To test these hypotheses, we used the same conditional mutant mouse model as in the RNAseq study and measured the effects in an *in vitro* culture system.



## GO terms related to neuronal morphogenesis



#### GO terms related to ion transport



**Figure 1. Pax6 deletion in the prethalamus caused upregulated expression of genes involved in neuronal morphogenesis and ion transport related GO terms.** (A-A') Immunohistochemistry showing Pax6 expression overlapping with Tuj1 expression, a marker for postmitotic neurons, in the E13.5 prethalamus of the control littermate. PTh, prethalamus, Th, thalamus, Ctx, cortex. (B-B') Pax6 immunohistochemistry at E13.5 showing CAG<sup>CreER</sup>-induced loss of Pax6 in the prethalamus following


tamoxifen administration at E9.5. (C) The top 14 most highly enriched, non-redundant GO terms related to neuronal morphogenesis and (D) the top 7 most highly enriched, non-redundant GO terms related to ion transport in the Pax6 cKO prethalamus. Scale bar: (A) 250 µm; (A', B-B') 100µm. See also Supplementary Table 1.

#### Pax6 loss from prethalamic neurons caused defects of neurite extension

Administration of tamoxifen at E9.5 to Pax6<sup>fl/fl</sup> embryos ubiquitously expressing the Cre recombinase from a CAG<sup>CreER</sup> allele caused Pax6 loss from E11.5 onwards (Quintana-Urzainqui *et al.*, 2018). No Pax6 protein was detected in the tissue when we harvested the embryos for dissociated cell culture at E13.5 (Figure 1B-B'). We termed these embryos conditional knockouts (Pax6cKOs, CAG<sup>CreER</sup> Pax6<sup>fl/fl</sup>). Their littermates that were heterozygous for the Pax6<sup>fl</sup> allele were used as the control group (Ctrl, CAG<sup>CreER</sup> Pax6<sup>fl/+</sup>), as they continue to express Pax6 in a normal pattern (Simpson *et al.*, 2009; Quintana-Urzainqui *et al.*, 2018).

The process of dissection of the E13.5 prethalamus for dissociated cell culture is detailed by the schematic representation in Figure 2A-E. The majority of Ctrl and Pax6cKO prethalamic cells were positive for Tuj1 and neuritogenesis had already begun at 1 day in vitro (1DIV) (Figure 2G-G'). Most Ctrl and Pax6cKO prethalamic neurons displayed one longest neurite, which was presumably the developing axon, and several shorter neurites (Figure 2G-L'). The longest neurites developed many branches and small protrusions, especially at later stages (Figure 2J-L'). By visual inspection, the general morphologies of the Ctrl and Pax6cKO prethalamic neurons were similar (Figure 2G-L'). Three parameters were measured at each DIV: the number of neurites, the length of the longest neurite and the total length of neurites (Figure 2F-F'). Pax6cKO prethalamic neurons had fewer neurites than Ctrl neurons at 1DIV but not after longer culture (Figure 2M). The longest neurites and the total neurite lengths in Pax6cKO prethalamic neurons were shorter than in Ctrls from 1-3 DIV (Figure 2N-O). However, after 3DIV the longest neurites elongated more rapidly in Pax6cKO than in Ctrl neurons and they became significantly longer at 5DIV and 6DIV (Figure 2N). These results indicate that, after a delayed start, Pax6cKO prethalamic neurons developed a relatively normal complement of neurites, the longest of which later outstripped their equivalents in Ctrl neurons.

At all 6 DIVs, the majority of the prethalamic neurons displayed polarised morphologies with a single longest neurite (axon) and multiple shorter neurites (dendrites) (Figure 2G-L'). We examined this further, since the RNAseq analysis had indicated that Pax6cKO prethalamic cells upregulated expression of genes encoding components of the Par3/6 complex. We used the localised distribution of Par3 as an indicator of neuronal polarity (Nishimura *et al.*, 2004). Our results showed no significant differences in the amount and distribution of Par3 within the neurites and the soma between Ctrl and Pax6cKO prethalamic neurons at 3DIV (Supplementary Figure 1). We concluded that the establishment of neuronal polarity was not affected in *Pax6*-deleted prethalamic neurons.





(A-E) Schematic summary of the dissociated cell culture of the E13.5 prethalamus.

(F-F') Example of how the number of neurites (F), the length of the longest neurite and the total length of neurites (F') were measured for each neuron. Scale bar:  $20\mu m$ 

(G-L') Example of the morphology of prethalamic neurons labelled with Tuj1 from both genotypes on each day of the cell culture. Scale bar: 10µm.


(M-O) Quantification of the number of neurites (M), length of longest neurite (N) and total length of neurites (O) in Ctrl and Pax6cKO prethalamic neurons cultured 1-6DIV. Mixed-effect model, at least 100 neurons from each genotype were collected from each litter on each of the six days of cell culture. Three litters in total (n=3). \*\*\*: P<0.001, \*\*: 0.001<P<0.01, \*: 0.01<P<0.05. Mean with standard error of mean (SEM).

#### Pax6 loss from prethalamic neurons altered AIS length and location

We investigated AIS formation with immunohistochemistry for AnkG and VGSC in dissociated prethalamic neurons after 7 and 9 DIV.

At both 7DIV and 9DIV, the majority of the prethalamic neurons of both genotypes developed a single AIS (Figure 3A-D, magenta segments) where the profiles of AnkG and VGSC expression (quantified as illustrated in Figure. 3A'-D') coincided at the proximal end of a neurite. We observed a tendency for the AISs to extend further from the soma in Pax6cKO neurons (Figure. 3E-G). The average length of the AIS measured with VGSC at 7DIV and with AnkG at 9DIV were significantly higher in Pax6cKO neurons (Figure. 3H, I). In no case were densities of staining (i.e. the average fluorescence intensity per unit length of neurite) with either marker different between the two genotypes (Figure. 3J, K). Figure 3L-M summarises the lengthening and distal extension of the AIS in the prethalamic neurons after 7 and 9 DIV.

These results suggest that Pax6 plays a role in controlling the formation of the AISs of prethalamic neurons, influencing their positions relative to the soma and aspects of their sizes.



**Figure 3.** Loss of Pax6 changed the length and location of the AIS in the prethalamic neurons. (A-D) Examples of immunohistochemistry staining showing localised distribution of AnkG or VGSC at the proximal end of the axon, marking the AIS, in prethalamic neurons cultured for 7 DIV. Scale bar: 10µm.

(A'-D') Examples of normalised fluorescence intensity of AnkG or VGSC along the axon, which we term AIS intensity profile. The peak is defined as where the normalised fluorescence intensity is the highest. The start location (close to the soma) and the end location are defined as where the normalised fluorescence intensities fall to 33% of peak intensity (Grubb and Burrone, 2010).

(E) Alignment of the AIS length and location marked by the two markers (AnkG and VGSC) in Ctrl and Pax6cKO prethalamic neurons cultured for 7 and 9 DIV.

(F-G) Comparison of the start location of the AIS marked by either AnkG or VGSCs in Ctrl and Pax6cKO prethalamic neurons cultured for 7 and 9 DIV.

(H-I) Comparison of the length of the AIS marked by either AnkG or VGSCs in Ctrl and Pax6cKO prethalamic neurons cultured for 7 and 9 DIV. Length of the AIS is defined as the distance between the start and the end location.

(J-K) Comparison of the normalised intensity of the AIS marked by either AnkG or VGSCs in Ctrl and Pax6cKO prethalamic neurons cultured for 7 and 9 DIV.

(L-M) Schematic summary of changes of AIS length and location in Pax6cKO prethalamic neurons at 7 and 9 DIV.

Mixed-effect model, at least 30 neurons from each genotype were collected from each litter on either 7 or 9 day of cell culture. Three litters in total (n=3). \*\*\*: P<0.001, \*\*: 0.001<P<0.01, \*: 0.01<P<0.05. (E) Mean with SEM. (F-K) Median with interquartile range.

## Loss of Pax6 affected the electrophysiological properties of prethalamic neurons

Since the reported changes of the AIS and the expression of voltage-gated ion channels might change neuronal excitability and electrical functions (Grubb and Burrone, 2010; Grubb *et al.*, 2011; Kaphzan *et al.*, 2011; Höfflin *et al.*, 2017; Booker *et al.*, 2020), we performed whole-cell patch-clamp on prethalamic neurons cultured for 7 and 9 DIV.


To induce action potentials (APs), we stimulated the prethalamic neurons with small depolarising current steps (-30pA to 140pA, 10pA increments, 1000ms) from -60mV. Prethalamic neurons of both genotypes at both ages were able to fire APs (Figure 4A-B'). From 7 to 9DIV, the resting membrane potentials (RMPs) became significantly more negative in both the Ctrl and Pax6cKO prethalamic neurons, as expected in maturing neurons (Linaro *et al.*, 2019), with no significant differences between genotypes (Figure 4C). Figure 4D-E showed how membrane potentials changed in response to specific negative (hyperpolarising) and positive (depolarising) current inputs before rheobases were reached. At 7DIV but not at 9DIV, negative current inputs hyperpolarised membrane potentials significantly more in Pax6cKO than in Ctrl neurons (Figure 4D-E). Although no differences were found at 7DIV (p=0.0549), rheobase became significantly lower in Pax6 cKOs at 9DIV (p=0.0077) (Figure 4F). The AP threshold remained unchanged at both ages (Figure 4G).

We examined the waveforms of the first APs fired by the Ctrl and the Pax6cKO prethalamic neurons in response to the current stimulus at their rheobases. Figure 4H-I shows the overlayed example traces of the first APs shown in Figure 4A-B'. AP halfwidth was significantly broader in Pax6cKOs at both ages and AP height was significantly lower in Pax6cKOs at 7DIV (Figure 4J-K).

Prethalamic neurons from both genotypes were able to fire multiple APs after rheobases were reached but, at 7DIV, Pax6cKO prethalamic neurons showed a significant reduction in maximum AP number (Figure 4L). The highest AP firing frequency in the Pax6cKO neurons at 7DIV ( $7\pm$  1.4Hz) was significantly lower than

that in the Ctrl neurons (18.6  $\pm$  1.9Hz). This phenotype was recovered at 9DIV, when Pax6cKO and Ctrl neurons fired comparable maximum numbers of APs (Figure 4M). At 9DIV, losing Pax6 also caused a leftward shift in the current-frequency response (Figure 4M), indicating that a similar number of APs were generated using a lower amplitude of current stimulus in the Pax6cKO neurons.

We concluded that Pax6 can affect the activity of the prethalamic neurons, affecting their excitability level, the waveforms of somatic APs and their ability to fire APs repetitively.





(A-B') Representative membrane potential traces recorded in Ctrl and Pax6cKO prethalamic neurons cultured for 7 and 9DIV. The lowest traces corresponded to how the membrane potential changed in response to a -30pA current injection. The red traces in each figure showed membrane potential

traces at rheobases and APs being fired. The highest trace corresponded to membrane potentials in response to 40pA added to rheobase.

(C, F, G) Comparison of resting membrane potential, rheobase and threshold potential in Ctrl and Pax6cKO prethalamic neurons cultured for 7 and 9 DIV.

(D-E) I-V curves in Ctrl and Pax6cKO prethalamic neurons cultured for 7 and 9 DIV.

(H-I) Aligned and overlayed traces of the first APs fired at rheobases by the Ctrl and Pax6cKO prethalamic neurons cultured for 7 and 9 DIV.

(J-K) Comparison of the half-width and height of the first AP at rheobases in Ctrl and Pax6cKO prethalamic neurons cultured for 7 and 9 DIV.

(L-M) Current frequency plot for Ctrl and Pax6cKO prethalamic neurons cultured for 7 and 9DIV, indicating differences in AP firing frequency in response to applied current steps.

Mixed effect model, 16 neurons from Ctrl 7DIV, 13 neurons from Pax6cKO 7DIV, 14 neurons from Ctrl 9DIV, 12 neurons from Pax6cKO 9DIV. 4 litters for each genotype at both DIVs (n=4). \*\*\*: P<0.001,

\*\*: 0.001<P<0.01, \*: 0.01<P<0.05. (C-G, J-K) Mean with SEM. (D-E) Mean with SD.

## Discussion

Pax6 is mostly expressed in specific neural progenitor cells, where its functions have been extensively studied, and its importance for the maturation of post-mitotic neurons and their functional properties is less well understood. Our study provides evidence that Pax6 plays a role in the morphological growth and functional development of prethalamic post-mitotic neurons.

We showed that Pax6 deletion timed to coincide with the onset of prethalamic neurogenesis disturbed the morphogenesis of prethalamic neurons. Our results indicated that Pax6 facilitates the early stages of axon elongation. At later stages, however, Pax6 limited axon elongation of prethalamic neurons, probably by repressing expression of cytoskeletal effector genes. Mechanisms limiting axon elongation might be important because most prethalamic neurons project only short distances (Martinez-Ferre and Martinez, 2012; Willis *et al.*, 2015), unlike neighbouring thalamic neurons, many of which project long thalamocortical axons (TCAs). There is evidence that early short-range prethalamic axons innervating the thalamus act as scaffolds for the descending TCAs entering the prethalamus en route to the cortex (Ono *et al.*, 2014; Clegg *et al.*, 2015; Feng *et al.*, 2016). Misrouting of TCAs is a known phenotype of Pax6<sup>-/-</sup> mutant mice (Auladell *et al.*, 2000; Pratt *et al.*, 2000; Simpson *et al.*, 2009; Price *et al.*, 2012; Clegg *et al.*, 2015; Feng *et al.*, 2016; Quintana-Urzainqui *et al.*, 2020), and our findings suggest that one factor contributing to this might be disrupted prethalamic axonal growth.

It is unclear what causes delayed neuronal morphogenesis in Pax6cKO prethalamic neurons at early stages of cell culture. Previous studies proposed that the establishment of neuronal polarity can be one of the speed-limiting steps of neuronal morphogenesis in vitro (Bradke and Dotti, 2000; Barnes and Polleux, 2009; Yogev and Shen, 2017). Our analysis on the distribution of PAR3 and the formation of AIS have shown that the establishment of neuronal polarity is unlikely to be affected in the prethalamic neurons by Pax6 deletion.

We showed that Pax6 affects AIS development in prethalamic neurons. To our knowledge, this is the first evidence that Pax6 impacts on the formation of this

important cellular structure. AIS assembly is considered an intrinsic property of neurons, requiring no extracellular or glial-dependent cues (Ogawa and Rasband, 2008). The observed lengthening of the AIS was in line with the upregulated expression of VGSCs and AnkG shown in the RNAseq data, but their distal shift was unexpected. As the master regulator of AIS assembly, AnkG specifies AIS formation and VGSC clustering (Zhou *et al.*, 1998; Rasband, 2010), but little is known about the mechanisms that contribute to the enrichment and targeting of AnkG to the proximal axon and specify the location of the AIS (Rasband, 2010; Berger *et al.*, 2018; Leterrier, 2018).

We also showed that Pax6 can affect the electrophysiological properties of prethalamic neurons. The distal shift of the AIS in Pax6cKO neurons might have contributed to the widening of the AP waveforms recorded from their soma. These recordings would have been mainly the backpropagated APs generated at the AIS (Kole, Letzkus and Stuart, 2007) and increasing the distance between the AIS and the soma would increase voltage attenuation, resulting in wider and slower APs. The underlying causes for the decrease in rheobase in the Pax6cKO prethalamic neurons are less clear. Changes in the AIS length and location could be a factor since previous studies have shown that both increased length and distal relocation of the AIS can promote excitability (Grubb and Burrone, 2010; Buffington and Rasband, 2011; Kaphzan et al., 2011; Höfflin et al., 2017; Jamann, Jordan and Engelhardt, 2018; Goethals and Brette, 2020). Changes of AIS geometry alone are unlikely to provide a full explanation, however, since theoretical modelling suggests that they would produce a modest decrease (a few mV) in threshold potential (Goethals and Brette, 2020), for which we found no evidence. Therefore, it is likely that changes outside the AIS contributed to the decrease in rheobase in Pax6cKO prethalamic neurons. The surprising observation that 7DIV Pax6cKO prethalamic neurons fired significantly fewer APs and entered the state of depolarization block with significantly lower amplitude of current stimulus despite having significantly longer AISs might be explained in two ways. First, there might be defects at the AISs; second, RNAseq data suggested upregulation of several voltage-gated potassium channels belonging to the Kv4 family (Kv4.1(KCND1), Kv4.2(KCND2) and Kv4.3(KCND3), Supplementary Table 2), which can efficiently reduce repetitive firing (Fransén and Tigerholm, 2010; Hermanstyne et al., 2017; Kim et al., 2020).

In conclusion, our results suggest that Pax6 acts in developing mouse prethalamic neurons to limit their axonal extension, fine-tune the exact location and extent of their AISs and ensure their normal somatic AP waveforms and excitability.

## Acknowledgement

The authors would like to thank Dr Adam Jackson and Dr Javier Moral-Sanz for assistance with experimental set up for whole-cell patch-clamp recordings, Dr Michael Daw and Dr Sam Booker for comments on the manuscript and all of the members of the Developmental Biology User Group for helpful discussion. We thank our funders: MRC, BBSRC, Wellcome Trust and SIDB.

## **Author Contributions**

T.T., I.Q.-U., T.P., and D.J.P. were involved in overall conceptualization, data interpretation, and manuscript preparation. T.T. carried out wet-laboratory experiments; Z.K. and T.T. did the bioinformatics and statistics. D.J.P. acquired funding and I.Q.-U., T.P. and D.J.P. supervised the work.

## **Declaration of Interests**

The authors declare no competing interest.

## **STAR Methods**

#### Key Resource Table

Reagent or Resource	Source	Identifier
Antibodies		
Rabbit polyclonal anti-Pax6 (1:200)	BioLegend	Cat#901301, RRID:
		AB_2565003
Mouse monoclonal anti-Pax6 (1:10)	A gift from Prof. V van Heyningen, AD2.38 Simpson <i>et al.</i> , 2009	N/A
Mouse monoclonal anti-Beta III tubulin (Tuj1) (1:200)	Abcam	Cat# ab18207, RRID: AB_444319
Mouse monoclonal anti-Ankyrin-G, clone	Antibodies Inc.	Cat# 75-146
N106/36 (1:200)		
Monoclonal Anti-Sodium Channel, Pan	Sigma-Aldrich	Cat# S88091MG
antibody produced in mouse (1:100)		
Rabbit polyclonal Anti-Partitioning-	Millipore	Cat# 07-330
defective 3 Antibody (1:100)		

Goat polyclonal Anti-GFP antibody	Abcam	Cat# ab6673
(1:200)		
Chicken polyclonal Anti-GFP antibody	Abcam	Cat# ab13970
(1:200)		
Goat anti-mouse biotinylated secondary		Cat# BA-9200,
antibody (1:200)	Vector laboratories	RRID:AB_2336171
Goat anti-rabbit biotinylated secondary		 Cat# BA-1000,
antibody (1:200)	Vector laboratories	RRID:AB_2313606
Donkey anti-mouse Alexa 568 secondary		 Cat# A10037,
antibody (1:200)	Thermo Fisher Scientific	RRID:AB_2534013
Donkey anti-rabbit Alexa 647 secondary		
antibody (1:200)	Invitrogen	Cat # A-31573
Donkey anti-chicken Alexa 488 secondary		
antibody (1:200)	Stratech Scientific Limited	Cat# 703-545-155-JIR
Donkey anti-rabbit Alexa 568 secondary		
antibody (1:200)	Invitrogen	Cat # A10042
Donkey anti-goat Alexa 488 secondary		
antibody (1:200)	Invitrogen	Cat # A-11055
Donkey anti-rat Alexa 488 secondary		Cat# A-21208,
antibody (1:200)	Thermo Fisher Scientific	RRID:AB_141709
Streptavidin, Alexa Fluor 488 conjugate		Cat# S11223,
	Thermo Fisher Scientific	
antibody (1:200)	Protoino	RRID:AB_2336881
Chemicals, Peptides, and Recombinant		T5040 040 40540 00 4
Tamoxifen	Sigma-Aldrich	T5648; CAS: 10540-29-1
Critical Commercial Assays		
DAB peroxidase substrate kit	Vector Laboratories	SK4100
Papain Dissociation System	Worthington Biochemical Corp	Cat# LK003150
Experimental Models:		
Organisms/Strains		
	This paper Hayashi and	
Mouse: CAGGCre-ERTM; RCE (GFP)	McMahon, 2002 Sousa et	N/A
	al., 2009	
Mouse: Pax6loxP	Simpson et al., 2009	N/A
Software and Algorithms		
Graphpad Prism 8	Graphpad software	
pClamp	Molecular Devices	
Matlab_R2018b	Mathworks	
Fiji (Image J)	Schindelin et al., 2012	https://fiji.sc/

IMARIS 9.1.2	Bitplane	

#### **Resource Availability**

#### Lead contact

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact,

#### Materials Availability

This study did not generate new unique reagents.

#### Data and Code Availability

All data and code generated in this study will be made available upon reasonable request.

The published article (Quintana-Urzainqui *et al.*, 2018) includes all the RNAseq dataset analysed during this study.

#### Experimental Model and Subject Details

#### Mice colony maintenance and transgenic lines

Mouse lines used to generate tamoxifen-induced deletion of Pax6 throughout the embryo were as described in (Quintana-Urzainqui *et al.*, 2018). Pregnant mice were given 10mg of tamoxifen (Sigma) by oral gavage on embryonic day 9.5 (E9.5) to induce Pax6loxP deletion and embryos were collected on E13.5. Embryos heterozygous for the Pax6flox allele (Pax6<sup>fl/+</sup>; CAGG<sup>CreER</sup>) were used as controls (Ctrl) as previous studies have shown no detectable defects in the forebrain of Pax6<sup>fl/+</sup> embryos (Simpson *et al.*, 2009). Embryos carrying two copies of the floxed Pax6 allele (Pax6<sup>fl/fl</sup>; CAGG<sup>CreER</sup>) were the experimental conditional knock-out (cKO) group.

For staging of embryos, the first day the vaginal plug was detected was considered as embryonic day 0.5 (E0.5).

All animal husbandry was conducted in accordance with the UK Animal (Scientific Procedures) Act 1986 regulations and all procedures were approved by Edinburgh University's Animal Ethics Committee.

#### **Method Details**

#### Dissociated prethalamic cell culture preparation

#### Dissection of the prethalamus

To dissect the prethalamus, embryos from E13.5 were collected and decapitated. The neural tube was separated from the epidermal and mesodermal tissue and cut in half along the dorsal and ventral midline (Figure 2A-B). From E9.5, morphologic segmentation of the diencephalon starts and the diencephalic prosomeres become apparent from E10-11 as ventricular ridges and lateral wall bulges appear (18). These morphological landmarks are used to distinguish prethalamus from the surrounding tissue (the thalamus and the eminentia thalami) during dissection (Figure 2C).

#### Dissociated cell culture

After being cut out, the prethalamus from the two halves of the neural tube of the same embryo were put together and chopped into smaller pieces for dissociated cell culture using the Papain Dissociation System (Worthington Biochemical Corp.) according to the manufacturer's protocol (Figure 2C-E). The prethalamus from each embryo was dissociated and cultured individually. The number of cells obtained after dissociation was measured using a haemocytometer. Additionally, trypan blue staining was used to determine the ratio of viable to damaged cells. To adjust the plating density of the cell culture, cells obtained after dissociation were resuspended using a certain amount of culture medium (Advanced DMEM/Neurobasal medium 1:1, supplemented with N2 (100x) and B27 (50x) neural supplement, Thermo Fisher Scientific). 130µl of the culture medium containing the desired number of resuspended cells was then added onto the 9mm circular coverslips (Fischer Scientific) coated with Poly-L-lysine and Laminin (Thermo Fisher Scientific). Due to the surface tension of the culture medium, the culture medium containing the

dissociated cells would stay within and fill up the realm of the coverslips. The cell cultures were then incubated at 37°C with 5% CO2 for 1 hour to allow the cells to attach to the coverslips. In this way, all the cells obtained after the dissociation was retained within the coverslip, and the exact cell density of plating could be calculated using the total amount of cells divided by the surface areas of the coverslips being used. The plating density of prethalamic cell culture used for studying neuronal morphogenesis and AIS formation was 20 cells/mm<sup>2</sup>, and the plating density of prethalamic cell culture used for electrophysiological recordings was 600 cells/mm<sup>2</sup>. After 1hr, 240µl of the culture medium was then added into each well of the 48-well plate (Greiner Bio-One) that contains the coverslip. The dissociated prethalamic cells were cultured for 1-9 days. Light microscopy was used to monitor the condition of cell cultures daily.

#### Genotyping

We dissected tissue from the tails of each embryo, extracted DNA and performed PCR amplification to detect the alleles of interest.

For the detection of the floxed Pax6 allele, PCR reaction was performed in a final volume of 25µl containing 1.5µl of extracted DNA, 0.5mM primer mix (Simpson et al. 2009, forward primer: 5'-AAA TGG GGG TGA AGT GTG AG-3'; reverse primer: 5'-TGC ATG TTG CCT GAA AGA AG-3'), 0.5 mM dNTPs mix, 1X PCR reaction buffer and 5U/µl Taq DNA Polymerase (Qiagen). PCR was performed with 35 cycles and a Tm of 59°C. The PCR product was subsequently run in a 2% agarose gel. Wild type allele results in a fragment of 156bp and floxed allele fragment was 195bp, therefore two bands indicated the heterozygous condition (used as controls) and one strong 195bp band identified the homozygous floxed allele condition (Pax6cKOs).

#### Histological processing and imaging

Sample processing for immunohistochemistry

Cryo-sections were obtained following methods described in (Quintana-Urzainqui *et al.*, 2018).

Cell culture samples were obtained by removing the coverslips containing the prethalamic neurons from the culture medium. 1x phosphate buffered saline (PBS) warmed to 37°C were used to rinse the prethalamic neurons for 3 times. For cell culture samples used in neuronal morphology and polarity studies, the prethalamic neurons were fixed in 4% PFA for 20 minutes. For cell culture samples used in AIS study, the prethalamic neurons were fixed in 2% PFA/4% sucrose for 10 minutes to prevent degradation of AnkG protein by the fixative. The cell culture samples were further rinsed with 1x PBS and kept in 1x PBS at 4°C until processed.

Fluorescent immunohistochemistry

Fluorescent immunohistochemistry on cryo-sections were performed as described in (Quintana-Urzainqui *et al.*, 2018).

Fluorescent immunohistochemistry on cell culture were performed as follows: fixed prethalamic neurons were rinsed with 0.1% Triton X-100 in 1xPBS (0.1% PBST) and permeabilised in 0.5% Triton X-100 in 1x PBS (0.5% PBST) for 10 minutes. Then cells were washed with 0.1% PBST for three times and further blocked with blocking solution (20% goat or donkey serum in 0.1% PBST) for 2 hours. Then the blocking serum containing primary antibodies was added to the cells for overnight incubation. On the second day, cells were washed with 0.1% PBST and further incubated with blocking serum containing the corresponding secondary antibodies (Streptavidin Alexa Fluor<sup>™</sup> 488, 546 or 647 conjugates; Thermo Fisher Scientific) for 1 hour. Cells were then washed with 1xPBS, and further incubated with DAPI (Thermo Fisher Scientific) for counterstaining of the nucleus. The coverslips were mounted in ProLong Gold Antifade Mountant (Thermo Fisher Scientific) for further imaging.

Imaging

Fluorescence images of the dissociated cells in the neuronal morphogenesis study were taken using a Leica DM5500B automated upright microscope connected to a DFC360FX camera. The route of acquiring images started from the upper-left corner towards the lower-right of the 9mm circular coverslip. Every image being taken was from an adjacent visual field of the previous image, in an attempt to cover as many cells on the coverslip as possible and without imaging the same cells twice.

Fluorescence images of the dissociated cells in the PAR3 study were taken using the Zeiss LSM800 confocal microscope with Airy Scan.

Fluorescence images of the dissociated cells in the AIS study were taken using the Andor Revolution XDi Spinning disk confocal microscope.

#### Whole-cell patch-clamp recording

For electrophysiological recordings on the dissociated prethalamic neurons cultured for 7 and 9 DIV, coverslips with attached prethalamic neurons were transferred to a submerged recording chamber perfused with carbonated ACSF (in mM: 150 NaCl, 2.8 KCl, 10 HEPES, 2 CaCl2, 1 MgCl2, 10 Glucose, pH7.3), at a flow rate of 4-6ml/min at 22-23°C. Prethalamic neurons were visualised with a digital camera (SciCam Pro, Scientifica) mounted on an upright microscope (BX61-WI, Olympus) and a 40x water-immersion objective lens (1.0 N.A., Olympus). Whole-cell patchclamp recordings were performed with a Multiclamp 700B amplifier (Molecular Devices), filtered at 10KHz with the built-in 4-pole Bessel Filter and digitised using a Digidata 1440A digitiser board (Molecular Devices) at 20kHz. Recording pipettes were pulled from borosilicate glass capillaries (Havard Apparatus, 30-0060) on a horizontal electrode puller (P-97, Sutter Instruments) to a tip resistance of 4-6 M $\Omega$ . Recording pipettes were filled with K-gluconate-based internal solution (in mM: 130 K-gluconate, 4 Glucose, 10 HEPES, 0.1 EGTA, 0.025 CaCl2, 20 Sucrose, pH=7.2, 290-300mOsm). Recording pipettes were positioned with a micromanipulator (Scientifica PatchStar). Data were acquired from cells with access resistance <  $25M\Omega$ . pClamp 10 (Axon Instruments) was used to generate the various analogue waveforms to control the amplifier and record the traces.

Resting membrane potential of the prethalamic neurons was recorded with current clamped with no current input (I=0 pA) for 30 seconds. Constant current was injected to hold the cells close to -60mV and I-V curve, rheobase and threshold was assessed by current injections from -30 to +140 pA for 1000 ms (10 pA steps). All AP properties were determined from the first AP elicited at rheobase. Analysis of electrophysiological data was performed offline using a custom-written Matlab script kindly provided by Dr Adam Jackson, blind to genotype.

#### Image analysis

#### Measurement of neurite length

Measurement of neurite length was performed using the freehand line tool in the FIJI package of ImageJ. Whole morphology of the neurons was marked by fluorescent immunohistochemistry reacting with the Tuj1 antibody, which labels the neuronspecific Class III β-tubulin of the cytoskeleton. For each Tuj1-positive cell, three parameters - the number of neurites, the length of the longest neurite and the total length of neurites were measured. A neurite was defined as a stable protrusion from the soma with strong Tuj1 staining. Protrusions from the soma that were thin and had faint Tuj1 staining were considered as either artefacts or filopodia, which mainly consist of F-actin and were not considered as neurites. The length of a neurite was measured by tracing down the neurite from the edge of the soma to the most distal edge of Tuj1 staining. Such measurement was performed for every neurite of each neuron analysed. The length of the longest neurite was the highest reading among these measurements of each neuron. All the protrusions, positive for Tuj1 staining that stemmed from the neurites were considered as branches. The length of each branch was measured from where it stemmed from the neurite to its furthest edge of Tuj1 staining. The total length of neurites for each neuron was calculated as the sum of the length of all the neurites and branches.

Measurement of PAR3 distribution

Measurement was performed with the IMARIS software (Bitplane, version 9.1.2). Dissociated prethalamic neurons cultured for 3DIV were marked by fluorescent immunohistochemistry reacting with antibodies for PAR3, GFP for whole-cell morphology and DAPI for counterstaining of the nucleus.

The surface function of IMARIS was utilised to create a new GFP channel. To do so, the signal intensity threshold was adjusted manually based on the specific situation of each neuron so that IMARIS was able to detect the space where the GFP signal is above that set threshold. This threshold was determined by fitting and adjusting different threshold values so that the GFP-positive space IMARIS detected optimally matched the actual cytoplasmic volume and included almost all the neurites and cytoplasmic protrusions. Places where their GFP signals were above this threshold but resided outside of the cytoplasm were manually deleted. In this way, a new GFP channel was created, which only included and highly resembled the entire cytoplasm of the neurons. Then a new PAR3 channel was created using the new GFP channel as the template of the cytoplasmic volume to exclude any Par3 staining outside of the cytoplasm. With this new PAR3 channel, we could then detect the highest intensity of PAR3 expression within the cytoplasm. Different thresholds were set for IMARIS to detect the cytoplasmic volumes in which the PAR3 intensities were above 75%, 50%, 25% and 10% of its own highest intensity value. This allowed us to quantify the cytoplasmic volume that had higher expression levels of PAR3 at each of these thresholds, and also visualise the distribution of different intensities of PAR3 within the cytoplasm.

#### Measurement of the intensity profile of AIS

The intensity profile of AIS was generated by tracing down the neurite bearing the localised expression of either AnkG or VGSC, 80µm from the edge of the soma, using the freehand line tool in the FIJI package of ImageJ, resulting in a graph with the level of AnkG or VGSC expression at each pixel from the soma corresponding to the specific distance from the soma.

#### **Quantification and Statistical Analysis**

All experiments were performed blind to genotype. All data was analysed with either a linear mixed-effect model (LMM) or its generalised form (GLMM), unless stated otherwise. The variability due to random effects (animal, litter) was taken into account, allowing for the calculation of the genotype effect size. Where reported, statistical significance was assumed if p<0.05.

## Supplemental Information


**Supplemental Table 1.** List of significantly up- and downregulated (adjusted p<0.05) genes and GO terms in the E13.5 prethalamus after induced acute Pax6 deletion at E9.5. Related to Figure 1.

Genes	LFC	P value	Description	
GEFs for R	GEFs for Rac			
Dock4	1.03	3.39E-10	dedicator of cytokinesis 4	
Dock2	0.86	0.00196	dedicator of cytokinesis 2	
Dock3	0.68	0.00300	dedicator of cytokinesis 3	
Dock9	0.66	0.00671	dedicator of cytokinesis 9	
Dock10	0.76	0.00339	dedicator of cytokinesis 10	
Dock8	0.95	0.00178	dedicator of cytokinesis 8	
Scaffold fo	r GEFs			
Elmo1	0.87	2.21E-10	engulfment and cell motility 1	
Scaffold fo	r CDC4	2		
Fgd1	0.57	0.00362	FYVE, RhoGEF and PH domain containing 1	
Fgd5	1.04	3.11E-05	FYVE, RhoGEF and PH domain containing 5	
Fgd2	0.67	0.00234	FYVE, RhoGEF and PH domain containing 2	
Fgd6	0.65	0.00503	FYVE, RhoGEF and PH domain containing 6	
GAP for Rh	GAP for Rho and Rac			
Srgap3	0.92	0.00086	SLIT-ROBO Rho GTPase activating protein 3	
Rac				
Rnd1	0.77	2.55E-07	Rho family GTPase 1	
Actin-bund	Actin-bundling			
Ablim1	0.59	0.00253	actin-binding LIM protein 1	
Ablim3	1.19	7.20E-07	actin binding LIM protein family, member 3	
Ablim2	0.91	0.00342	actin-binding LIM protein 2	
Strip2	1.80	4.32E-07	striatin interacting protein 2	
Anti-capping for actin				
Enah	0.67	0.00391	enabled homolog (Drosophila)	
Membrane	Membrane curvature			
Pacsin1	0.81	0.00546	protein kinase C and casein kinase substrate in neurons 1	
Microtubule polymerisation/bundling				

Mapb 1.16 4.90E-08 microtubule-associated protein 6   Map6 0.70 0.00732 microtubule-associated protein 6   Map2 0.32 0.01108 microtubule-associated protein 9   Mark1 0.76 0.00720 MAP/microtubule affinity-regulating kinase 1   Mark4 0.76 0.00425 adenomatosis polyposis coli 2   Apc 0.86 0.00425 adenomatosis polyposis coli 2   Apc 0.78 0.00820 adenomatosis polyposis coli 2   Cmp1 0.32 0.00312 collapsin response mediator protein 1   Dyps15 0.66 0.000201 intyrimidinase-like 5   Par3/6 complex 0.00481 treall ymphoma invasion and metastasis 1   Aringap3 0.59 0.01060 Rho GTPase activating protein 35   Smu11 0.53 0.00328 SMAD specific E3 ubiquitin protein ligase 1   Pard3b 0.80 0.00822 par-3 family cell polarity regulator beta   Apc 0.78 0.00820 adenomatosis polyposis coli   Cytoskeletor 0.00105 ankyrin 3, epithel					
Map90.600.00746microtubule-associated protein 9Map20.320.01108microtubule affnity-regulating kinase 1Mark40.760.0020MAP/microtubule affnity-regulating kinase 4Apc20.860.00485adenomatosis polyposis coli 2Apc0.780.00820adenomatosis polyposis coli 2Cmp10.320.00312collapsin response mediator protein 1Dys150.660.00484kinesin family member 3ATiam10.660.00481frotlen kinase C, zetaKif3a0.460.004821Tell ymphoma invasion and metastasis 1Arhgap350.590.01060Rho GTPase activating protein 35Smur110.530.00328SMAD specific E3 ubiquitin protein ligase 1Arhgap350.590.00328SMAD specific E3 ubiquitin protein ligase 1Ark31.190.00105ankyrin 3, epithelialSmur110.530.00328spectrin beta, non-erythrocyticArk31.190.00105ankyrin 3, epithelialSptbh1.170.00054spectrin beta, non-erythrocytic 1Sptbh1.390.00123sodium channel, voltage-gated, type II, betaScn2b0.770.00123sodium channel, voltage-gated, type II, betaScn2b0.770.00123sodium channel, voltage-gated, type II, betaScn2b0.770.00123sodium channel, voltage-gated, type II, betaScn2b0.00112sodium channel, voltage-gated, type II, betaScn2b0.00113 <td>Mapt</td> <td>1.16</td> <td>4.90E-08</td> <td>microtubule-associated protein tau</td>	Mapt	1.16	4.90E-08	microtubule-associated protein tau	
Map2 0.32 0.01108 microtubule-associated protein 2   Mark1 0.78 0.00014 MAP/microtubule affinity-regulating kinase 1   Mark4 0.76 0.00720 MAP/microtubule affinity-regulating kinase 1   Apc2 0.86 0.00485 adenomatosis polyposis coli   Apc 0.78 0.00620 adenomatosis polyposis coli   Crmp1 0.32 0.00312 collapsin response mediator protein 1   Dpys15 0.66 0.00500 dihydropyrimidinase-like 5   Par3/6 complex component Protex 0.37 0.00431   Protex 0.37 0.00431 protein kinase C, zeta   Kif3a 0.45 0.00484 kinesin family member 3A   Tiam1 0.66 0.00821 T cell lymphoma invasion and metastasis 1   Arhgap35 0.59 0.01060 Rho GTPase activating protein 13se   Smurf1 0.53 0.00822 par-3 family cell polarity regulator beta   Apc 0.78 0.00823 par-3 family cell polarity regulator beta   Apc 0.78 0.00025					
Mark1 0.78 0.00014 MAP/microtubule affinity-regulating kinase 1   Mark4 0.76 0.00720 MAP/microtubule affinity-regulating kinase 4   Apc2 0.86 0.00485 adenomatosis polyposis coli 2   Apc 0.78 0.00820 adenomatosis polyposis coli 2   Crmp1 0.32 0.00820 adenomatosis polyposis coli 2   Par3/6 compretexcomponent Terment Terment   Prkcz 0.37 0.00431 protein kinase C, zeta   Kif3a 0.45 0.00482 kinesin family member 3A   Tiam1 0.66 0.00821 T cell lymphoma invasion and metastasis 1   Arhgap35 0.59 0.01060 Rho GTPase activating protein 35   Smurf1 0.53 0.00820 adenomatosis polyposis coli   Cytoskeleton protein in the axominitial segment Anko 1.09 ankyrin 3, epithelial   Sptb 1.17 0.00054 spectrin beta, non-erythrocytic 1 Sptbn4   Sptbn4 1.36 4.52E-06 sodium channel, voltage-gated, type II, lepta   Scn3a 0.39				·	
Mark40.760.00720MAP/microtubule affinity-regulating kinase 4Apc20.860.00485adenomatosis polyposis coli 2Apc0.780.00820adenomatosis polyposis coli 2Crmp10.320.00312collapsin response mediator protein 1Dpys150.660.00500dihydropyrimidinase-like 5Par3/6 complexcomplexcollapsin response mediator protein 1Prkcz0.370.00431protein kinase C, zetaKif3a0.450.00484kinesin family member 3ATiam10.560.00821T cell lymphoma invasion and metastasis 1Arhgap350.590.01060Rho GTPase activating protein 35Smur110.530.00822par-3 family cell polarity regulator betaApc0.780.00820adenomatosis polyposis coliCytoskeleton proteininte axoninitial segmentAnk31.190.00105ankyrin 3, epithelialSptb1.170.00054spectrin beta, non-erythrocytic 1Sptbn11.030.00096spectrin beta, non-erythrocytic 4Voltage-gatedSodium channel, voltage-gated, type II, leptaScn3b0.722.96E-06sodium channel, voltage-gated, type II, leptaScn3b0.722.96E-06sodium channel, voltage-gated, type II, leptaScn3b0.722.96E-06sodium channel, voltage-gated, type III, laphaKcn4d1.070.00252sodium channel, voltage-gated, type III, laphaKcn4d0.610.0769potassium voltag				•	
Apc2 0.86 0.00485 adenomatosis polyposis coli 2   Apc 0.78 0.00820 adenomatosis polyposis coli   Crmp1 0.32 0.00312 collapsin response meditator protein 1   Dpys15 0.66 0.00500 dihydropyrimidinase-like 5   Par36 complex component P   Prkcz 0.37 0.00431 protein kinase C, zeta   Kif3a 0.45 0.00484 kinesin family member 3A   Tiam1 0.66 0.00821 T cell lymphoma invasion and metastasis 1   Arhgap35 0.59 0.01060 Rho GTPase activating protein 35   Smurf1 0.53 0.00822 par-3 family cell polarity regulator beta   Apc 0.78 0.00820 adenomatosis polyposis coli   Cytoskeleton protein in the axon initial segment Ank3 1.19 0.00105   Apt 1.30 0.00926 spectrin beta, non-erythrocytic 1   Sptbn1 1.36 4.52E-06 spectrin beta, non-erythrocytic 4   Voltage-gated Sodium channel, voltage-gated, type II, alpha Scn3a 0.39 0.00123 <td></td> <td></td> <td></td> <td></td>					
Apc0.780.00820adenomatosis polyposis coliCmp10.320.00312collapsin response mediator protein 1Dpysl50.660.00500dihydropyrimidinase-like 5Par3/6 comFex co					
Crmp1 0.32 0.00312 collapsin response mediator protein 1   Dpysl5 0.66 0.00500 dihydropyrimidinase-like 5   Par36 complex component Protein kinase C, zeta   Kif3a 0.45 0.00431 protein kinase C, zeta   Kif3a 0.45 0.00821 T cell lymphoma invasion and metastasis 1   Arhgap35 0.59 0.01600 Rho GTPase activating protein 35   Smurf1 0.53 0.00822 par-3 family cell polarity regulator beta   Apc 0.76 0.00822 par-3 family cell polarity regulator beta   Apc 0.76 0.00820 adenomasis polyposis coli   Cytoskeletor proteim in the axon initial segment Ank3 1.19 0.00105   Ank3 1.19 0.00096 spectrin beta, non-erythrocytic 1   Sptbn1 1.03 0.00096 spectrin beta, non-erythrocytic 4   Voltage-gated Socium channel, voltage-gated, type I, alpha Scn3b 0.77   Scn3b 0.72 2.96E-06 sodium channel, voltage-gated, type II, beta   Scn2b 0.58 0.00118 sodiu					
Dpysl50.660.00500dihydropyrimidinase-like 5Par3/6 complex componentPrkcz0.370.00431protein kinase C, zetaKif3a0.450.00484kinase C, zetaKif3a0.450.00484kinase C, zetaTiam10.660.00821T cell lymphoma invasion and metastasis 1Arhgap350.590.01060Rho GTPase activating protein 35Smurf10.530.00822par-3 family cell polarity regulator betaApc0.780.00822par-3 family cell polarity regulator betaApc0.780.00820alenomators polyposis coliCytoskeletorprotein the axorinitial segmentAnk31.190.00105alseptin beta, non-erythrocyticSptbn11.030.00096spectrin beta, non-erythrocytic 1Sptbn41.364.52E-06sodium channel, voltage-gated, type I, alphaScn3b0.722.96E-06sodium channel, voltage-gated, type II, betaScn2b0.580.00118sodium channel, voltage-gated, type III, betaScn2b0.580.0002sodium channel, voltage-gated, type III, betaScn2b0.590.0022member 4Kcn241.02<	-				
Par3/6 complex componentPrkcz0.370.00431protein kinase C, zetaKif3a0.450.00484kinesin family member 3ATiam10.660.00821T cell lymphoma invasion and metastasis 1Arhgap350.590.01060Rho GTPase activating protein 35Smurf10.530.00822par-3 family cell polarity regulator betaApc0.780.00820adenomatosis polyposis coliCytoskeleton protein in the axon initial segmentAnk31.190.00105ankyrin 3, epithelialSptbn11.030.00096spectrin beta, erythrocyticSptbn41.364.52E-06spectrin beta, non-erythrocytic 1Sptbn41.360.01123sodium channel, voltage-gated, type I, alphaScn3a0.722.96E-06sodium channel, voltage-gated, type II, betaScn2b0.580.00118sodium channel, voltage-gated, type II, betaScn2b0.580.00040member 4Potassium voltage-gated channel, shaker-related subfamily, member 4Kcna41.871.40E-76Kcnd10.610.00769potassium voltage-gated channel, Shaw-related subfamily, member 3Kcnd20.680.00912calcium voltage-gated channel, Shaw-related subfamily, member 4Kcnd10.610.00769potassium voltage-gated channel, Shaw-related subfamily, member 3Kcnd20.680.00912calcium channel, voltage-gated channel, Shal-related family, member 3Kcnd31.023.7	-				
Prkcz0.370.00431protein kinase C, zetaKif3a0.450.00484kinesin family member 3ATiam10.660.00821T cell lymphoma invasion and metastasis 1Arhgap350.590.01060Rho GTPase activating protein 35Smur110.530.00822par-3 family cell polarity regulator betaApc0.780.00822par-3 family cell polarity regulator betaApc0.780.00022par-3 family cell polarity regulator betaApc0.780.00023ankyrin 3, epithelialSytb1.190.00105ankyrin 3, epithelialSytb1.170.00054spectrin beta, erythrocyticSytbn11.030.00096spectrin beta, non-erythrocytic 1Sytbn41.364.52E-06spectrin beta, non-erythrocytic 4Voltage-gated, type I, alphaScn3a0.770.00123sodium channel, voltage-gated, type I, alphaScn3b0.722.96E-06sodium channel, voltage-gated, type II, betaScn3a0.390.00502sodium channel, voltage-gated, type II, alphaRapidly in-zutational (1.87)1.40E-16member 3Kcna41.871.40E-16member 3Kcnd40.790.00252member 4Kcnd40.610.00769potassium voltage-gated channel, Shaker-related subfamily, member 3Kcnd41.023.78E-10potassium voltage-gated channel, Shaker-related family, member 3Kcnd40.610.00769potassium voltage-gated cha				dihydropyrimidinase-like 5	
Kif3a 0.45 0.00484 kinesin family member 3A   Tiam1 0.66 0.00821 T cell lymphoma invasion and metastasis 1   Arhgap35 0.59 0.01060 Rho GTPase activating protein 35   Smurf1 0.53 0.00328 SMAD specific E3 ubiquitin protein ligase 1   Pard3b 0.80 0.00822 par-3 family cell polarity regulator beta   Apc 0.78 0.00820 adenomatosis polyposis coli   Cytoskeleton protein in the axon initial segment Ank3 1.19 0.00105   Ank3 1.19 0.00064 spectrin beta, non-erythrocytic   Sptbn1 1.03 0.00096 spectrin beta, non-erythrocytic 1   Sptbn4 1.36 4.52E-06 spectrin beta, non-erythrocytic 4   Voltage-gated too01013 sodium channel, voltage-gated, type I, alpha   Scn3b 0.72 2.96E-06 sodium channel, voltage-gated, type II, loeta   Scn2b 0.58 0.00118 sodium channel, voltage-gated, type III, loeta   Scn2a 0.39 0.00502 sodium voltage-gated channel, shaker-related subfamily, member 3					
Tiam10.660.00821T cell lymphoma invasion and metastasis 1Arhgap350.590.01060Rho GTPase activating protein 35Smurf10.530.00328SMAD specific E3 ubiquitin protein ligase 1Pard3b0.800.00822par-3 family cell polarity regulator betaApc0.780.00820adenomatosis polyposis coliCytoskeleton protein in the axor initial segmentAnk31.190.00105ankyrin 3, epithelialSptb1.170.00096spectrin beta, erythrocyticSptbn11.030.00096spectrin beta, non-erythrocytic 1Sptbn41.364.52E-06spectrin beta, non-erythrocytic 4Voltage-gated Sodium channel: (VGSCs)Scn1a0.770.00123sodium channel, voltage-gated, type I, alphaScn2b0.580.00118sodium channel, voltage-gated, type II, betaScn3a0.390.00502sodium channel, voltage-gated, type II, alphaRapidly inactivating A-type K+ channelpotassium voltage-gated channel, shaker-related subfamily, member 4Kcna41.871.40E-16potassium voltage gated channel, Shaw-related subfamily, member 3potassium voltage gated channel, Shal-related family, member 1Kcnd10.610.00769potassium voltage-gated channel, Shal-related family, member 3potassium voltage-gated channel, Shal-related family, member 3potassium voltage-gated channel, Shal-related family, member 3Kcnd10.610.00769potassium voltage-gated channel, Shal-related family, member 3		0.37	0.00431	protein kinase C, zeta	
Arhgap350.590.01060Rho GTPase activating protein 35Smurf10.530.00328SMAD specific E3 ubiquitin protein ligase 1Pard3b0.800.00822par-3 family cell polarity regulator betaApc0.780.00820adenomatosis polyposis coliCytoskeleon protein in the avor initial segmentAnk31.190.00054spectrin beta, erythrocyticSptbn1.170.00096spectrin beta, non-erythrocytic 1Sptbn41.364.52E-06spectrin beta, non-erythrocytic 4Voltage-gated Sodium channel, voltage-gated, type I, alphaScn1a0.770.00123sodium channel, voltage-gated, type II, alphaScn3b0.722.96E-06sodium channel, voltage-gated, type II, betaScn3a0.390.00502sodium channel, voltage-gated, type II, alphaRapidly inactivating A-type K+ channelpotassium voltage-gated channel, shaker-related subfamily, member 4Kcna41.871.40E-16potassium voltage gated channel, Shaw-related subfamily, member 3Kcnd10.610.00769potassium voltage gated channel, Shaw-related subfamily, member 3Kcnd20.849.81E-07potassium voltage-gated channel, Shah-related family, member 3Kcnd31.023.78E-10potassium voltage-gated channel, Shah-related family, member 3Kcnd20.680.00912calcium channel, voltage-gated channel, Shah-related family, member 3Kcnd31.023.78E-10potassium voltage-gated channel, Shah-related family, member 3<	Kif3a			kinesin family member 3A	
Smurf10.530.00328SMAD specific E3 ubiquitin protein ligase 1Pard3b0.800.00822par-3 family cell polarity regulator betaApc0.780.00820adenomatosis polyposis coliCytoskele	Tiam1	0.66	0.00821	T cell lymphoma invasion and metastasis 1	
Pard3b0.800.00822par-3 family cell polarity regulator betaApc0.780.00820adenomatosis polyposis coliCytoskeleton protein in the axon initial segmentAnk31.190.00105ankyrin 3, epithelialSptb1.170.00054spectrin beta, erythrocyticSptbn11.030.00096spectrin beta, non-erythrocytic 1Sptbn41.364.52E-06spectrin beta, non-erythrocytic 4Voltage-gated Sodium channels (VGSCs)Scn1a0.770.00123sodium channel, voltage-gated, type I, alphaScn3b0.722.96E-06sodium channel, voltage-gated, type II, betaScn3b0.722.96E-06sodium channel, voltage-gated, type II, betaScn3b0.722.96E-06sodium channel, voltage-gated, type II, alphaRapidly inactivating A-type K+ channelpotassium voltage-gated channel, shaker-related subfamily, member 4Kcn41.871.40E-16potassium voltage gated channel, Shaw-related subfamily, member 3potassium voltage gated channel, Shaw-related subfamily, member 4potassium voltage-gated channel, Shal-related family, member 1Kcnd10.610.00769potassium voltage-gated channel, Shal-related family, member 3Voltage-gated Ca2+ channelspotassium voltage-gated channel, Shal-related family, member 1Kcnd20.849.81E-07potassium voltage-gated channel, Shal-related family, member 3Cacna1e1.090.0012calcium channel, voltage-dapendent, Shal-related family, member 3Cacna1e0.849.81E-	Arhgap35	0.59	0.01060	Rho GTPase activating protein 35	
Apc0.780.00820adenomatosis polyposis coliCytoskeleton protein in the axon initial segmentAnk31.190.00105ankyrin 3, epithelialSptb1.170.00054spectrin beta, erythrocyticSptbn11.030.00096spectrin beta, non-erythrocytic 1Sptbn41.364.52E-06spectrin beta, non-erythrocytic 4Voltage-gated Sodium channels (VGSCs)Scn1a0.770.00123sodium channel, voltage-gated, type I, alphaScn3b0.722.96E-06sodium channel, voltage-gated, type II, betaScn3b0.722.96E-06sodium channel, voltage-gated, type II, betaScn3a0.390.00502sodium channel, voltage-gated, type III, alphaRapidly inactivating A-type K+ channelpotassium voltage-gated channel, shaker-related subfamily, member 4Kcnc31.020.00040member 4potassium voltage gated channel, Shaw-related subfamily, member 3potassium voltage gated channel, Shaw-related subfamily, member 3Kcnd10.610.00769potassium voltage-gated channel, Shal-related family, member 1Kcnd31.023.78E-10potassium voltage-gated channel, Shal-related family, member 3Kcnd20.849.81E-07potassium voltage-gated channel, Shal-related family, member 3Kcnd20.680.00930calcium channel, voltage-dependent, Shal-related family, member 3Kcnd20.680.00930calcium channel, voltage-dated channel, Shal-related family, member 3Kcnd20.680.00930		0.53			
Cytoskeleton protein in the axon initial segmentAnk31.190.00105ankyrin 3, epithelialSptb1.170.00054spectrin beta, erythrocyticSptbn11.030.00096spectrin beta, non-erythrocytic 1Sptbn41.364.52E-06spectrin beta, non-erythrocytic 4Voltage-gated Sotium channel, voltage-gated, type I, alphaScn1a0.770.00123sodium channel, voltage-gated, type I, alphaScn3b0.722.96E-06sodium channel, voltage-gated, type II, betaScn3a0.390.00502sodium channel, voltage-gated, type II, betaScn3a0.390.00502sodium channel, voltage-gated, type III, alphaRapidly inactivating A-type K+ channelpotassium voltage-gated channel, shaker-related subfamily, member 4Kcnc31.020.00040member 4potassium voltage gated channel, Shaw-related subfamily, member 3potassium voltage gated channel, Shaw-related subfamily, member 3Kcnd10.610.00769potassium voltage-gated channel, Shal-related family, member 1Kcnd31.023.78E-10potassium voltage-gated channel, Shal-related family, member 3Kcnd20.849.81E-07potassium voltage-gated channel, Shal-related family, member 3Kcnd20.680.00930calcium channel, voltage-gated channel, Shal-related family, member 3Kcnd20.849.81E-07potassium voltage-gated channel, Shal-related family, member 3Kcnd20.680.00930calcium channel, voltage-dependent, Shal-rel	Pard3b	0.80	0.00822	par-3 family cell polarity regulator beta	
Ank31.190.00105ankyrin 3, epithelialSptb1.170.00054spectrin beta, erythrocyticSptbn11.030.00096spectrin beta, non-erythrocytic 1Sptbn41.364.52E-06spectrin beta, non-erythrocytic 4Voltage-gated.type I, alphaSon1a0.770.00123sodium channel, voltage-gated, type I, alphaSon3b0.722.96E-06sodium channel, voltage-gated, type II, betaSon3b0.722.96E-06sodium channel, voltage-gated, type II, betaSon3a0.390.00502sodium channel, voltage-gated, type II, betaSon3a0.390.00502sodium channel, voltage-gated, type II, alphaRapidly invertive K-teamelPotassium voltage-gated channel, shaker-related subfamily, member 4Motassium voltage gated channel, shaker-related subfamily, member 3Notassium voltage gated channel, Shaw-related subfamily, member 3Kenc40.610.00040Notassium voltage gated channel, Shal-related family, member 1Kend31.023.78E-10potassium voltage-gated channel, Shal-related family, member 3Kend30.990.00012Calcium channel, voltage-gated channel, Shal-related family, member 3Kend30.020.02potassium voltage-gated channel, Shal-related family, member 3Kend31.023.78E-10potassium voltage-gated channel, Shal-rel	Арс	0.78	0.00820	adenomatosis polyposis coli	
Sptb1.170.00054spectrin beta, erythrocyticSptbn11.030.00096spectrin beta, non-erythrocytic 1Sptbn41.364.52E-06spectrin beta, non-erythrocytic 4Voltage-gated Sodium channels (VGSCs)Scn1a0.770.00123sodium channel, voltage-gated, type I, alphaScn3b0.722.96E-06sodium channel, voltage-gated, type II, betaScn2b0.580.00118sodium channel, voltage-gated, type II, betaScn3a0.390.00502sodium channel, voltage-gated, type II, alphaRapidly in=trivering A-type K+ channelpotassium voltage-gated channel, shaker-related subfamily, member 4Kcnc31.220.0040Kcnc40.790.00252potassium voltage gated channel, Shaw-related subfamily, member 3Kcnc40.610.00769potassium voltage-gated channel, Shal-related family, member 1Kcnd31.023.78E-10potassium voltage-gated channel, Shal-related family, member 1Kcnd20.849.81E-07potassium voltage-gated channel, Shal-related family, member 2Voltage-gated channel, Shal-related family, member 3Kcnd20.680.00012cacna1e1.090.0012calcium channel, voltage-dependent, R type, alpha 1E subunitCacna1a0.610.00114calcium channel, voltage-dependent, R type, alpha 1A subunitCacna141.872.98E-08calcium channel, voltage-dependent, R type, alpha 1A subunitCacna141.872.98	Cytoskelet	Cytoskeleton protein in the axon initial segment			
Sptbn11.030.00096spectrin beta, non-erythrocytic 1Sptbn41.364.52E-06spectrin beta, non-erythrocytic 4Voltage-gated Sodium channels (VGSCs)Scn1a0.770.00123sodium channel, voltage-gated, type I, alphaScn3b0.722.96E-06sodium channel, voltage-gated, type III, betaScn2b0.580.00118sodium channel, voltage-gated, type III, betaScn3a0.390.00502sodium channel, voltage-gated, type III, alphaRapidly inactivating A-type K+ channelpotassium voltage-gated channel, shaker-related subfamily, member 4Kcna41.871.40E-16potassium voltage gated channel, Shaw-related subfamily, member 4Kcnc31.020.00040member 4potassium voltage gated channel, Shaw-related subfamily, member 3Kcnc40.790.00252member 4potassium voltage gated channel, Shaw-related subfamily, member 4Kcnd10.610.00769potassium voltage-gated channel, Shal-related family, member 1Kcnd20.849.81E-07potassium voltage-gated channel, Shal-related family, member 3Kcnd20.680.00930cacna1e1.090.0012cacna1e1.090.0012cacna1a0.610.00114caclium channel, voltage-dependent, R type, alpha 1E subunitCacna1a0.610.00114calcium channel, voltage-dependent, P/Q type, alpha 1A subunitCacna1a0.610.00114calcium channel, voltage-dep	Ank3	1.19	0.00105	ankyrin 3, epithelial	
Sptbn41.364.52E-06spectrin beta, non-erythrocytic 4Voltage-gated Sodium channel, voltage-gated, type I, alphaScn1a0.770.00123sodium channel, voltage-gated, type I, alphaScn3b0.722.96E-06sodium channel, voltage-gated, type III, betaScn2b0.580.00118sodium channel, voltage-gated, type II, betaScn3a0.390.00502sodium channel, voltage-gated, type II, betaRapidly instructivating A-type K+ channelpotassium voltage-gated channel, shaker-related subfamily, member 4Kcna41.871.40E-16member 4Kcnc31.020.00040member 3potassium voltage gated channel, Shaw-related subfamily, member 3potassium voltage-gated channel, Shaw-related subfamily, member 4Kcnc40.790.00252member 4Kcnd10.610.00769potassium voltage-gated channel, Shal-related family, member 1Kcnd31.023.78E-10potassium voltage-gated channel, Shal-related family, member 3Kcnd20.849.81E-07potassium voltage-gated channel, Shal-related family, member 1Kcnd31.023.78E-10potassium voltage-gated channel, Shal-related family, member 3Kcnd20.680.00930calcium channel, voltage-dependent, R type, alpha 1E subunitCacna1e1.090.0012calcium channel, voltage-dependent, R type, alpha 1A subunitCacna1a0.610.00114calcium channel, voltage-dependent, R type, alpha 1A subunitCacna1g1.214.11E-07calcium channel,	Sptb	1.17	0.00054	spectrin beta, erythrocytic	
Voltage-gated Sodium channels (VGSCs)Scn1a0.770.00123sodium channel, voltage-gated, type I, alphaScn3b0.722.96E-06sodium channel, voltage-gated, type III, betaScn2b0.580.00118sodium channel, voltage-gated, type III, betaScn3a0.390.00502sodium channel, voltage-gated, type III, alphaRapidly inactivating A-type K+ channelpotassium voltage-gated channel, shaker-related subfamily, member 4Kcna41.871.40E-16potassium voltage gated channel, Shaw-related subfamily, member 4Kcnc31.020.00040member 3potassium voltage gated channel, Shaw-related subfamily, member 4potassium voltage gated channel, Shaw-related subfamily, member 4Kcnc40.790.00252potassium voltage-gated channel, Shaw-related subfamily, member 4Kcnc40.610.00769potassium voltage-gated channel, Shal-related family, member 1Kcnd10.610.00769potassium voltage-gated channel, Shal-related family, member 3Kcnd20.849.81E-07potassium voltage-gated channel, Shal-related family, member 2Voltage-gated Ca2+ channelsCacna1e1.090.00012calcium channel, voltage-dependent, R type, alpha 1E subunitCacna2d20.680.00930calcium channel, voltage-dependent, alpha 2/delta subunit 2Cacna1a0.610.00114calcium channel, voltage-dependent, alpha 2/delta subunit 4Cacna1g1.214.11E-07calcium channel, voltage-dependent, T type, alpha 1G subunit </td <td>Sptbn1</td> <td>1.03</td> <td>0.00096</td> <td>spectrin beta, non-erythrocytic 1</td>	Sptbn1	1.03	0.00096	spectrin beta, non-erythrocytic 1	
Scn1a0.770.00123sodium channel, voltage-gated, type I, alphaScn3b0.722.96E-06sodium channel, voltage-gated, type III, betaScn2b0.580.00118sodium channel, voltage-gated, type II, betaScn3a0.390.00502sodium channel, voltage-gated, type III, alphaRapidly inactivating A-type K+ channelKcna41.871.40E-16potassium voltage-gated channel, shaker-related subfamily, member 4Kcnc31.020.00040potassium voltage gated channel, Shaw-related subfamily, member 3Kcnc40.790.00252potassium voltage-gated channel, Shaw-related subfamily, member 4Kcnd10.610.00769potassium voltage-gated channel, Shaw-related subfamily, member 4Kcnd20.849.81E-07potassium voltage-gated channel, Shal-related family, member 1Kcnd31.023.78E-10potassium voltage-gated channel, Shal-related family, member 2Voltage-gated Ca2+ channelCacna1e1.090.00012calcium channel, voltage-dependent, R type, alpha 1E subunitCacna1a0.610.00114calcium channel, voltage-dependent, alpha 2/delta subunit 2Cacna1a0.610.00114calcium channel, voltage-dependent, alpha 2/delta subunit 4Cacna1g1.214.11E-07calcium channel, voltage-dependent, T type, alpha 1G subunit	Sptbn4	1.36	4.52E-06	spectrin beta, non-erythrocytic 4	
Scn3b0.722.96E-06sodium channel, voltage-gated, type III, betaScn2b0.580.00118sodium channel, voltage-gated, type III, betaScn3a0.390.00502sodium channel, voltage-gated, type III, alphaRapidly inactivating A-type K+ channelpotassium voltage-gated channel, shaker-related subfamily, member 4Kcna41.871.40E-16potassium voltage gated channel, Shaw-related subfamily, member 3Kcnc40.790.00252member 4potassium voltage gated channel, Shaw-related subfamily, member 3Kcnd10.610.00769potassium voltage-gated channel, Shal-related family, member 1Kcnd31.023.78E-10potassium voltage-gated channel, Shal-related family, member 3Kcnd20.849.81E-07potassium voltage-gated channel, Shal-related family, member 3Kcnd20.840.00012calcium channel, voltage-dependent, R type, alpha 1E subunitCacna1e1.090.00112calcium channel, voltage-dependent, alpha 2/delta subunit 2Cacna1a0.610.00114calcium channel, voltage-dependent, alpha 2/delta subunit 4Cacna1g1.214.11E-07calcium channel, voltage-dependent, T type, alpha 1G subunit	Voltage-ga	ted Sod	ium channe	ls (VGSCs)	
Scn2b0.580.00118sodium channel, voltage-gated, type II, betaScn3a0.390.00502sodium channel, voltage-gated, type II, alphaRapidly inactivating A-type K+ channelpotassium voltage-gated channel, shaker-related subfamily, member 4Kcna41.871.40E-16potassium voltage gated channel, Shaw-related subfamily, member 3Kcnc31.020.00040member 3potassium voltage gated channel, Shaw-related subfamily, member 4member 4Kcnd10.610.00769potassium voltage-gated channel, Shal-related family, member 1Kcnd31.023.78E-10potassium voltage-gated channel, Shal-related family, member 3Kcnd20.849.81E-07potassium voltage-gated channel, Shal-related family, member 3Kcnd20.680.00012calcium channel, voltage-gated channel, Shal-related family, member 3Kcnd20.849.81E-07potassium voltage-gated channel, Shal-related family, member 3Kcnd20.680.00930calcium channel, voltage-dependent, R type, alpha 1E subunitCacna1e1.090.0012calcium channel, voltage-dependent, R type, alpha 1A subunitCacna2d41.872.98E-08calcium channel, voltage-dependent, alpha 2/delta subunit 4Cacna1g1.214.11E-07calcium channel, voltage-dependent, T type, alpha 1G subunit	Scn1a	0.77	0.00123	sodium channel, voltage-gated, type I, alpha	
Scn3a0.390.00502sodium channel, voltage-gated, type III, alphaRapidly inactivating A-type K+ channelpotassium voltage-gated channel, shaker-related subfamily, member 4Kcna41.871.40E-16potassium voltage gated channel, shaker-related subfamily, member 4Kcnc31.020.00040member 3Kcnc40.790.00252member 4Kcnd10.610.00769potassium voltage gated channel, Shaw-related subfamily, member 4Kcnd20.849.81E-07potassium voltage-gated channel, Shal-related family, member 3Kcnd20.849.81E-07potassium voltage-gated channel, Shal-related family, member 2Voltage-gated Ca2+channelCacna1e1.090.00012calcium channel, voltage-dependent, R type, alpha 1E subunitCacna2d20.680.00930calcium channel, voltage-dependent, alpha 2/delta subunit 2Cacna1a0.610.00114calcium channel, voltage-dependent, alpha 2/delta subunit 4Cacna1g1.214.11E-07calcium channel, voltage-dependent, T type, alpha 1G subunit	Scn3b	0.72	2.96E-06	sodium channel, voltage-gated, type III, beta	
Rapidly inactivating A-type K+ channelKcna41.871.40E-16potassium voltage-gated channel, shaker-related subfamily, member 4Kcna41.871.40E-16member 4potassium voltage gated channel, Shaw-related subfamily, member 3potassium voltage gated channel, Shaw-related subfamily, member 3Kcnc40.790.00252member 4Kcnd10.610.00769potassium voltage-gated channel, Shal-related family, member 1Kcnd31.023.78E-10potassium voltage-gated channel, Shal-related family, member 3Kcnd20.849.81E-07potassium voltage-gated channel, Shal-related family, member 3Kcnd20.849.00012calcium channel, voltage-gated channel, Shal-related family, member 2Voltage-gated Ca2+ channelsCacna1e1.090.00012Cacna1a0.610.00114calcium channel, voltage-dependent, R type, alpha 1E subunitCacna2d41.872.98E-08calcium channel, voltage-dependent, alpha 2/delta subunit 4Cacna1g1.214.11E-07calcium channel, voltage-dependent, T type, alpha 1G subunit	Scn2b	0.58	0.00118	sodium channel, voltage-gated, type II, beta	
Kcna41.871.40E-16potassium voltage-gated channel, shaker-related subfamily, member 4Kcna41.871.40E-16member 4Kcnc31.020.00040member 3potassium voltage gated channel, Shaw-related subfamily, member 3potassium voltage gated channel, Shaw-related subfamily, member 4Kcnc40.790.00252member 4Kcnd10.610.00769potassium voltage-gated channel, Shal-related family, member 1Kcnd31.023.78E-10potassium voltage-gated channel, Shal-related family, member 3Kcnd20.849.81E-07potassium voltage-gated channel, Shal-related family, member 2Voltage-gated Ca2+channel,voltage-gated channel, Shal-related family, member 2Cacna1e1.090.00012calcium channel, voltage-dependent, R type, alpha 1E subunitCacna2d20.680.00930calcium channel, voltage-dependent, alpha 2/delta subunit 2Cacna1a0.610.00114calcium channel, voltage-dependent, alpha 2/delta subunit 4Cacna1g1.214.11E-07calcium channel, voltage-dependent, T type, alpha 1G subunit	Scn3a	0.39	0.00502	sodium channel, voltage-gated, type III, alpha	
Kcna41.871.40E-16member 4Kcnc31.020.00040member 3Kcnc40.790.00252potassium voltage gated channel, Shaw-related subfamily, member 4Kcnd10.610.00769potassium voltage-gated channel, Shal-related family, member 1Kcnd31.023.78E-10potassium voltage-gated channel, Shal-related family, member 3Kcnd20.849.81E-07potassium voltage-gated channel, Shal-related family, member 3Kcnd20.849.81E-07potassium voltage-gated channel, Shal-related family, member 2Voltage-gated Ca2+ channelscalcium channel, voltage-dependent, R type, alpha 1E subunitCacna1e1.090.00112calcium channel, voltage-dependent, alpha 2/delta subunit 2Cacna1a0.610.00114calcium channel, voltage-dependent, alpha 2/delta subunit 4Cacna1g1.214.11E-07calcium channel, voltage-dependent, T type, alpha 1G subunit	Rapidly ina	ctivatin	g A-type K+		
Kcnc31.02potassium voltage gated channel, Shaw-related subfamily, member 3Kcnc40.790.00252potassium voltage gated channel, Shaw-related subfamily, member 4Kcnd10.610.00769potassium voltage-gated channel, Shal-related family, member 1Kcnd31.023.78E-10potassium voltage-gated channel, Shal-related family, member 3Kcnd20.849.81E-07potassium voltage-gated channel, Shal-related family, member 2Voltage-gated Ca2+ channelspotassium voltage-gated channel, Shal-related family, member 2Cacna1e1.090.00012calcium channel, voltage-dependent, R type, alpha 1E subunitCacna2d20.680.00930calcium channel, voltage-dependent, alpha 2/delta subunit 2Cacna1a0.610.00114calcium channel, voltage-dependent, alpha 2/delta subunit 4Cacna1g1.214.11E-07calcium channel, voltage-dependent, T type, alpha 1G subunit	Kcna/	1 87	1 /0=-16		
Kcnc31.020.00040member 3Kcnc40.790.00252potassium voltage gated channel, Shaw-related subfamily, member 4Kcnd10.610.00769potassium voltage-gated channel, Shal-related family, member 1Kcnd31.023.78E-10potassium voltage-gated channel, Shal-related family, member 3Kcnd20.849.81E-07potassium voltage-gated channel, Shal-related family, member 2Voltage-gated Ca2+channelspotassium voltage-gated channel, Shal-related family, member 2Cacna1e1.090.00012calcium channel, voltage-dependent, R type, alpha 1E subunitCacna2d20.680.00930calcium channel, voltage-dependent, alpha 2/delta subunit 2Cacna1a0.610.00114calcium channel, voltage-dependent, Alpha 2/delta subunit 4Cacna1g1.214.11E-07calcium channel, voltage-dependent, T type, alpha 1G subunit	Топан	1.07	1.402-10		
Kcnc40.790.00252member 4Kcnd10.610.00769potassium voltage-gated channel, Shal-related family, member 1Kcnd31.023.78E-10potassium voltage-gated channel, Shal-related family, member 3Kcnd20.849.81E-07potassium voltage-gated channel, Shal-related family, member 2Voltage-gated Ca2+ channelsCacna1e1.090.00012calcium channel, voltage-dependent, R type, alpha 1E subunitCacna2d20.680.00930calcium channel, voltage-dependent, alpha 2/delta subunit 2Cacna1a0.610.00114calcium channel, voltage-dependent, P/Q type, alpha 1A subunitCacna1g1.214.11E-07calcium channel, voltage-dependent, T type, alpha 1G subunit	Kcnc3	1.02	0.00040	member 3	
Kcnd10.610.00769potassium voltage-gated channel, Shal-related family, member 1Kcnd31.023.78E-10potassium voltage-gated channel, Shal-related family, member 3Kcnd20.849.81E-07potassium voltage-gated channel, Shal-related family, member 2Voltage-gated Ca2+ channelsCacna1e1.090.00012calcium channel, voltage-dependent, R type, alpha 1E subunitCacna2d20.680.00930calcium channel, voltage-dependent, alpha 2/delta subunit 2Cacna1a0.610.00114calcium channel, voltage-dependent, P/Q type, alpha 1A subunitCacna2d41.872.98E-08calcium channel, voltage-dependent, alpha 2/delta subunit 4Cacna1g1.214.11E-07calcium channel, voltage-dependent, T type, alpha 1G subunit	Kcnc4	0.79	0.00252		
Kcnd31.023.78E-10potassium voltage-gated channel, Shal-related family, member 3Kcnd20.849.81E-07potassium voltage-gated channel, Shal-related family, member 2Voltage-gated Ca2+ channelsCacna1e1.090.00012calcium channel, voltage-dependent, R type, alpha 1E subunitCacna2d20.680.00930calcium channel, voltage-dependent, alpha 2/delta subunit 2Cacna1a0.610.00114calcium channel, voltage-dependent, P/Q type, alpha 1A subunitCacna2d41.872.98E-08calcium channel, voltage-dependent, alpha 2/delta subunit 4Cacna1g1.214.11E-07calcium channel, voltage-dependent, T type, alpha 1G subunit				potassium voltage-gated channel, Shal-related family, member 1	
Kcnd20.849.81E-07potassium voltage-gated channel, Shal-related family, member 2Voltage-gated Ca2+ channelsCacna1e1.090.00012calcium channel, voltage-dependent, R type, alpha 1E subunitCacna2d20.680.00930calcium channel, voltage-dependent, alpha 2/delta subunit 2Cacna1a0.610.00114calcium channel, voltage-dependent, P/Q type, alpha 1A subunitCacna2d41.872.98E-08calcium channel, voltage-dependent, alpha 2/delta subunit 4Cacna1g1.214.11E-07calcium channel, voltage-dependent, T type, alpha 1G subunit					
Voltage-gated Ca2+ channelsCacna1e1.090.00012calcium channel, voltage-dependent, R type, alpha 1E subunitCacna2d20.680.00930calcium channel, voltage-dependent, alpha 2/delta subunit 2Cacna1a0.610.00114calcium channel, voltage-dependent, P/Q type, alpha 1A subunitCacna2d41.872.98E-08calcium channel, voltage-dependent, alpha 2/delta subunit 4Cacna1g1.214.11E-07calcium channel, voltage-dependent, T type, alpha 1G subunit					
Cacna1e1.090.00012calcium channel, voltage-dependent, R type, alpha 1E subunitCacna2d20.680.00930calcium channel, voltage-dependent, alpha 2/delta subunit 2Cacna1a0.610.00114calcium channel, voltage-dependent, P/Q type, alpha 1A subunitCacna2d41.872.98E-08calcium channel, voltage-dependent, alpha 2/delta subunit 4Cacna1g1.214.11E-07calcium channel, voltage-dependent, T type, alpha 1G subunit					
Cacna2d20.680.00930calcium channel, voltage-dependent, alpha 2/delta subunit 2Cacna1a0.610.00114calcium channel, voltage-dependent, P/Q type, alpha 1A subunitCacna2d41.872.98E-08calcium channel, voltage-dependent, alpha 2/delta subunit 4Cacna1g1.214.11E-07calcium channel, voltage-dependent, T type, alpha 1G subunit				calcium channel, voltage-dependent, R type, alpha 1E subunit	
Cacna1a0.610.00114calcium channel, voltage-dependent, P/Q type, alpha 1A subunitCacna2d41.872.98E-08calcium channel, voltage-dependent, alpha 2/delta subunit 4Cacna1g1.214.11E-07calcium channel, voltage-dependent, T type, alpha 1G subunit					
Cacna2d41.872.98E-08calcium channel, voltage-dependent, alpha 2/delta subunit 4Cacna1g1.214.11E-07calcium channel, voltage-dependent, T type, alpha 1G subunit					
Cacna1g 1.21 4.11E-07 calcium channel, voltage-dependent, T type, alpha 1G subunit					
Hcn2 0.95 1.12E-05 hyperpolarization-activated, cyclic nucleotide-gated K+ 2					

Hcn4	0.70	0.00481	hyperpolarization-activated, cyclic nucleotide-gated K+ 4
Hcn3	0.40	0.00852	hyperpolarization-activated, cyclic nucleotide-gated K+ 3

**Supplementary Table 2.** List of genes found in the neuronal morphogenesis and ion transport GO terms that encode proteins with specific neuronal functions. LFC, log-fold change.



Supplementary Figure 1. Distribution of Par3 proteins within the developing prethalamic neurons at 3DIV. (A, B) Prethalamic neurons from the Ctrl (A) and Pax6cKO (B) embryos were cultured for 3DIV and stained for Par3, GFP and DAPI. (C, D) Par3 expression within the cytoplasm of the neurons. (E1-F1) Par3 expression within the cytoplasm when the intensity threshold was set at 75% of the maximum intensity of the Par3 channel. The majority of the Par3 volumes were distributed within the soma. However, Par3 volumes were also found in the stem of the longest neurites (yellow arrowheads). (E2-F2) Par3 expression within the cytoplasm when the intensity threshold was set at 50% of the maximum intensity of the Par3 channel. More Par3 volumes were detected in the soma, the stem of the longest neurites (yellow arrowheads), as well as in other neurites (grey arrowheads). (E3-F3) Par3 expression within the cytoplasm when the intensity threshold was set at 25% of the maximum intensity of the Par3 channel. Par3 volumes within the cytoplasm continued to increase. Par3 volumes could be found at the tip of the longest neurites (yellow arrowheads) and other neurites (grev and blue arrowheads), (E4-F4) Par3 expression within the cytoplasm when the intensity threshold was set at 10% of the maximum intensity of the Par3 channel. PAR3 volumes had filled up the cytoplasm and could be found at almost all the tip of the neurites and protrusions (orange arrowheads). (E'-F') Zoom in on the boxed area in E1 and F1. Scale bars: A-D, 15μm, E1-F5, 10μm, E'-F', 5µm. (G-N) Comparison of Par3 volumes and percentage of Par3 volumes against the cytoplasmic volume between the Ctrl and the Pax6cKO prethalamic neurons. 10 neurons from the Ctrl and Pax6cKO genotypes were measured. Three litters in total (n=3). Each dot (data point) represented the value of Par3 volume (G, I, K, M) or Par3 volume/ total cytoplasmic volume (H, J, L, N) from each neuron at a specific threshold. The data points of the neurons from the same litter were marked with the same colour. Data were analysed with mixed-effect model. Mean ± SEM. \*: P<0.05.

## References

Auladell, C. *et al.* (2000) 'The early development of thalamocortical and corticothalamic projections in the mouse', *Anatomy and embryology*. Springer, 201(3), pp. 169–179.

Barnes, A. P. and Polleux, F. (2009) 'Establishment of axon-dendrite polarity in developing neurons', *Annual review of neuroscience*, 32.

Berger, S. L. *et al.* (2018) 'Localized myosin II activity regulates assembly and plasticity of the axon initial segment', *Neuron*. Elsevier, 97(3), pp. 555–570.

Booker, S. A. *et al.* (2020) 'Input-Output Relationship of CA1 Pyramidal Neurons Reveals Intact Homeostatic Mechanisms in a Mouse Model of Fragile X Syndrome', *Cell Reports*. Elsevier, 32(6), p. 107988.

Bradke, F. and Dotti, C. G. (2000) 'Establishment of neuronal polarity: lessons from cultured hippocampal neurons', *Current opinion in neurobiology*. Elsevier, 10(5), pp. 574–581.

Buffington, S. A. and Rasband, M. N. (2011) 'The axon initial segment in nervous system disease and injury', *European Journal of Neuroscience*. Wiley Online Library, 34(10), pp. 1609–1619.

Caballero, I. M. *et al.* (2014) 'Cell-autonomous repression of Shh by transcription factor Pax6 regulates diencephalic patterning by controlling the central diencephalic organizer', *Cell reports*. Elsevier, 8(5), pp. 1405–1418.

Clegg, J. M. *et al.* (2015) 'Pax6 is required intrinsically by thalamic progenitors for the normal molecular patterning of thalamic neurons but not the growth and guidance of their axons', *Neural development*. BioMed Central, 10(1), p. 26.

Coutinho-Budd, J. *et al.* (2012) 'The F-BAR domains from srGAP1, srGAP2 and srGAP3 regulate membrane deformation differently', *Journal of cell science*. The Company of Biologists Ltd, 125(14), pp. 3390–3401.

Cvekl, A. and Callaerts, P. (2017) 'PAX6: 25th anniversary and more to learn', *Experimental eye research*. Elsevier, 156, pp. 10–21.

Duan, D. *et al.* (2013) 'Spatiotemporal expression patterns of Pax6 in the brain of embryonic, newborn, and adult mice', *Brain Structure and Function*. Springer, 218(2), pp. 353–372.

Engelkamp, D. *et al.* (1999) 'Role of Pax6 in development of the cerebellar system', *Development*. The Company of Biologists Ltd, 126(16), pp. 3585–3596.

Feng, J. *et al.* (2016) 'Celsr3 and Fzd3 organize a pioneer neuron scaffold to steer growing thalamocortical axons', *Cerebral Cortex*. Oxford University Press, 26(7), pp. 3323–3334.

Flynn, K. C. (2013) 'The cytoskeleton and neurite initiation', *Bioarchitecture*. Taylor & Francis, 3(4), pp. 86–109.

Fransén, E. and Tigerholm, J. (2010) 'Role of A-type potassium currents in excitability, network synchronicity, and epilepsy', *Hippocampus*. Wiley Online Library, 20(7), pp. 877–887.

Fukata, Y. *et al.* (2002) 'CRMP-2 binds to tubulin heterodimers to promote microtubule assembly', *Nature cell biology*. Nature Publishing Group, 4(8), pp. 583–591.

Georgala, P. A., Carr, C. B. and Price, D. J. (2011) 'The role of Pax6 in forebrain development', *Developmental neurobiology*. Wiley Online Library, 71(8), pp. 690–709.

Goethals, S. and Brette, R. (2020) 'Theoretical relation between axon initial segment geometry and excitability', *Elife*. eLife Sciences Publications Limited, 9, p. e53432. Grubb, M. S. *et al.* (2011) 'Short-and long-term plasticity at the axon initial segment',

*Journal of Neuroscience*. Soc Neuroscience, 31(45), pp. 16049–16055.

Grubb, M. S. and Burrone, J. (2010) 'Activity-dependent relocation of the axon initial segment fine-tunes neuronal excitability', *Nature*. Nature Publishing Group, 465(7301), pp. 1070–1074.

Hanson, I. and Van Heyningen, V. (1995) 'Pax6: more than meets the eye', *Trends in Genetics*. Elsevier, 11(7), pp. 268–272.

Hermanstyne, T. O. *et al.* (2017) 'Acute knockdown of Kv4. 1 regulates repetitive firing rates and clock gene expression in the suprachiasmatic nucleus and daily rhythms in locomotor behavior', *Eneuro*. Society for Neuroscience, 4(3).

Höfflin, F. *et al.* (2017) 'Heterogeneity of the axon initial segment in interneurons and pyramidal cells of rodent visual cortex', *Frontiers in Cellular Neuroscience*. Frontiers, 11, p. 332.

Hu, W. *et al.* (2009) 'Distinct contributions of Na v 1.6 and Na v 1.2 in action potential initiation and backpropagation', *Nature neuroscience*. Nature Publishing Group, 12(8), pp. 996–1002.

Jamann, N., Jordan, M. and Engelhardt, M. (2018) 'Activity-dependent axonal plasticity in sensory systems', *Neuroscience*. Elsevier, 368, pp. 268–282.

Kaphzan, H. *et al.* (2011) 'Alterations in intrinsic membrane properties and the axon initial segment in a mouse model of Angelman syndrome', *Journal of Neuroscience*. Soc Neuroscience, 31(48), pp. 17637–17648.

Kikkawa, T. *et al.* (2019) 'The role of Pax6 in brain development and its impact on pathogenesis of autism spectrum disorder', *Brain research*. Elsevier, 1705, pp. 95–103.

Kim, K.-R. *et al.* (2020) 'Kv4. 1, a key ion channel for low frequency firing of dentate granule cells, is crucial for pattern separation', *Journal of Neuroscience*. Soc Neuroscience, 40(11), pp. 2200–2214.

Kole, M. H. P. *et al.* (2008) 'Action potential generation requires a high sodium channel density in the axon initial segment', *Nature neuroscience*. Nature Publishing Group, 11(2), pp. 178–186.

Kole, M. H. P., Letzkus, J. J. and Stuart, G. J. (2007) 'Axon initial segment Kv1 channels control axonal action potential waveform and synaptic efficacy', *Neuron*. Elsevier, 55(4), pp. 633–647.

Kole, M. H. P. and Stuart, G. J. (2008) 'Is action potential threshold lowest in the axon?', *Nature neuroscience*. Nature Publishing Group, 11(11), pp. 1253–1255. Kunisaki, Y. *et al.* (2006) 'DOCK2 is a Rac activator that regulates motility and polarity during neutrophil chemotaxis', *The Journal of cell biology*. Rockefeller University Press, 174(5), pp. 647–652.

Lai, H. C. and Jan, L. Y. (2006) 'The distribution and targeting of neuronal voltagegated ion channels', *Nature Reviews Neuroscience*. Nature Publishing Group, 7(7), pp. 548–562.

Lalli, G. (2014) 'Regulation of neuronal polarity', *Experimental cell research*. Elsevier, 328(2), pp. 267–275.

Leterrier, C. (2018) 'The axon initial segment: an updated viewpoint', *Journal of Neuroscience*. Soc Neuroscience, 38(9), pp. 2135–2145.

Li, Y.-H. *et al.* (2009) 'Rnd1 regulates axon extension by enhancing the microtubule destabilizing activity of SCG10', *Journal of Biological Chemistry*. ASBMB, 284(1), pp. 363–371.

Linaro, D. *et al.* (2019) 'Xenotransplanted human cortical neurons reveal speciesspecific development and functional integration into mouse visual circuits', *Neuron*. Elsevier, 104(5), pp. 972–986.

Manuel, M. N. et al. (2015) 'Regulation of cerebral cortical neurogenesis by the Pax6

transcription factor', *Frontiers in cellular neuroscience*. Frontiers, 9, p. 70. Martinez-Ferre, A. and Martinez, S. (2012) 'Molecular regionalization of the diencephalon', *Frontiers in neuroscience*. Frontiers, 6, p. 73.

Mi, D. *et al.* (2013) 'Pax6 exerts regional control of cortical progenitor proliferation via direct repression of Cdk6 and hypophosphorylation of pRb', *Neuron*. Elsevier, 78(2), pp. 269–284.

Namekata, K. *et al.* (2010) 'Dock3 induces axonal outgrowth by stimulating membrane recruitment of the WAVE complex', *Proceedings of the National Academy of Sciences*. National Acad Sciences, 107(16), pp. 7586–7591.

Nishimura, T. *et al.* (2004) 'Role of the PAR-3–KIF3 complex in the establishment of neuronal polarity', *Nature cell biology*. Nature Publishing Group, 6(4), pp. 328–334. Norris, A. D., Dyer, J. O. and Lundquist, E. A. (2009) 'The Arp2/3 complex, UNC-115/abLIM, and UNC-34/Enabled regulate axon guidance and growth cone filopodia formation in Caenorhabditis elegans', *Neural development*. Springer, 4(1), p. 38. Ogawa, Y. and Rasband, M. N. (2008) 'The functional organization and assembly of the axon initial segment', *Current opinion in neurobiology*. Elsevier, 18(3), pp. 307–313.

Ono, K. *et al.* (2014) 'Development of the prethalamus is crucial for thalamocortical projection formation and is regulated by Olig2', *Development*. Oxford University Press for The Company of Biologists Limited, 141(10), pp. 2075–2084.

Pratt, T. *et al.* (2000) 'A role for Pax6 in the normal development of dorsal thalamus and its cortical connections', *Development*. The Company of Biologists Ltd, 127(23), pp. 5167–5178.

Price, D. J. *et al.* (2012) 'The importance of combinatorial gene expression in early mammalian thalamic patterning and thalamocortical axonal guidance', *Frontiers in neuroscience*. Frontiers, 6, p. 37.

Quan, A. and Robinson, P. J. (2013) 'Syndapin–a membrane remodelling and endocytic F-BAR protein', *The FEBS journal*. Wiley Online Library, 280(21), pp. 5198–5212.

Quintana-Urzainqui, I. *et al.* (2018) 'Tissue-Specific Actions of Pax6 on Proliferation and Differentiation Balance in Developing Forebrain Are Foxg1 Dependent', *Iscience*. Elsevier, 10, pp. 171–191.

Quintana-Urzainqui, I. *et al.* (2020) 'The role of the diencephalon in the guidance of thalamocortical axons in mice', *Development*. Oxford University Press for The

Company of Biologists Limited, 147(12).

Rasband, M. N. (2010) 'The axon initial segment and the maintenance of neuronal polarity', *Nature Reviews Neuroscience*. Nature Publishing Group, 11(8), pp. 552–562.

Reinhard, M., Jarchau, T. and Walter, U. (2001) 'Actin-based motility: stop and go with Ena/VASP proteins', *Trends in biochemical sciences*. Elsevier, 26(4), pp. 243–249.

Sainath, R. and Gallo, G. (2015) 'Cytoskeletal and signaling mechanisms of neurite formation', *Cell and tissue research*. Springer, 359(1), pp. 267–278.

Shi, S.-H. *et al.* (2004) 'APC and GSK-3β are involved in mPar3 targeting to the nascent axon and establishment of neuronal polarity', *Current Biology*. Elsevier, 14(22), pp. 2025–2032.

Da Silva, J. S. and Dotti, C. G. (2002) 'Breaking the neuronal sphere: regulation of the actin cytoskeleton in neuritogenesis', *Nature Reviews Neuroscience*. Nature Publishing Group, 3(9), pp. 694–704.

Simpson, T. I. *et al.* (2009) 'Normal ventral telencephalic expression of Pax6 is required for normal development of thalamocortical axons in embryonic mice', *Neural development*. Springer, 4(1), p. 19.

Stiess, M. and Bradke, F. (2011) 'Neuronal polarization: the cytoskeleton leads the way', *Developmental neurobiology*. Wiley Online Library, 71(6), pp. 430–444.

Stoykova, A. et al. (1996) 'Forebrain patterning defects in Small eye mutant mice',

Development. The Company of Biologists Ltd, 122(11), pp. 3453–3465.

Ueda, S. *et al.* (2008) 'Dock4 regulates dendritic development in hippocampal neurons', *Journal of neuroscience research*. Wiley Online Library, 86(14), pp. 3052–3061.

Willis, A. M. *et al.* (2015) 'Open-loop organization of thalamic reticular nucleus and dorsal thalamus: a computational model', *Journal of neurophysiology*. American Physiological Society Bethesda, MD, 114(4), pp. 2353–2367.

Witte, H. and Bradke, F. (2008) 'The role of the cytoskeleton during neuronal polarization', *Current opinion in neurobiology*. Elsevier, 18(5), pp. 479–487. Xiao, Y. *et al.* (2013) 'The atypical guanine nucleotide exchange factor Dock4 regulates neurite differentiation through modulation of Rac1 GTPase and actin dynamics', *Journal of Biological Chemistry*. ASBMB, 288(27), pp. 20034–20045. Yogev, S. and Shen, K. (2017) 'Establishing neuronal polarity with environmental

and intrinsic mechanisms', *Neuron*. Elsevier, 96(3), pp. 638–650. Zhou, D. *et al.* (1998) 'AnkyrinG is required for clustering of voltage-gated Na channels at axon initial segments and for normal action potential firing', *The Journal of cell biology*. The Rockefeller University Press, 143(5), pp. 1295–1304.